LISTA DE ATUALIZAÇÃO EM DOENÇA DE CHAGAS
Ano IV n°134__________________________________02.09.2009
1. Update on seroprevalence of anti-Trypanosoma cruzi antibodies among blood donors
in northeast Mexico.
Galavíz-Silva L, Molina-Garza DP, González-Santos MA, Mercado-Hernández R,
González-Galavíz JR, Rosales-Encina JL, Molina-Garza ZJ.
Am J Trop Med Hyg. 2009 Sep;81(3):404-6.
2. Trypanosoma cruzi circulating in the southern region of the State of Mexico
(Zumpahuacan) are pathogenic: a dog model.
Barbabosa-Pliego A, Díaz-Albiter HM, Ochoa-García L, Aparicio-Burgos E, LópezHeydeck SM, Velásquez-Ordoñez V, Fajardo-Muñoz RC, Díaz-González S, De OcaJimenez RM, Barbosa-Mireles M, Guzmán-Bracho C, Estrada-Franco JG, Garg NJ,
Vázquez-Chagoyán JC.
Am J Trop Med Hyg. 2009 Sep;81(3):390-5.
3. Transmission dynamics of Trypanosoma cruzi determined by low-stringency single
primer polymerase chain reaction and southern blot analyses in four indigenous
communities of the Sierra Nevada de Santa Marta, Colombia.
Rodríguez IB, Botero A, Mejía-Jaramillo AM, Marquez EJ, Ortiz S, Solari A, TrianaChávez O.
Am J Trop Med Hyg. 2009 Sep;81(3):396-403.
4. Experimental Chagas' disease in orchiectomized Calomys callosus infected with the
CM strain of Trypanosoma cruzi.
Pinto AC, Caetano LC, Levy AM, Fernandes RD, Santos CD, Prado Jr JC.
Exp Parasitol. 2009 Aug 18. [Epub ahead of print]
5. A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: A potential
anti-protozoa and anti-tumor agent.
Benítez J, Guggeri L, Tomaz I, Pessoa JC, Moreno V, Lorenzo J, Avilés FX, Garat B,
Gambino D.
J Inorg Biochem. 2009 Jul 24. [Epub ahead of print]
6. Aetiological treatment with itraconazole or ketoconazole in individuals with
Trypanosoma cruzi/HIV co-infection.
de Almeida EA, Silva EL, Guariento ME, Aoki FH, Pedro Rde J.
Ann Trop Med Parasitol. 2009 Sep;103(6):471-6.
7. Chronic Human Infection with Trypanosoma cruzi Drives CD4+ T Cells to Immune
Senescence.
Albareda MC, Olivera GC, Laucella SA, Alvarez MG, Fernandez ER, Lococo B, Viotti
R, Tarleton RL, Postan M.
J Immunol. 2009 Aug 19. [Epub ahead of print]
8. The molecular epidemiology and phylogeography of Trypanosoma cruzi and parallel
research on Leishmania: looking back and to the future.
Miles MA, Llewellyn MS, Lewis MD, Yeo M, Baleela R, Fitzpatrick S, Gaunt MW,
Mauricio IL.
Parasitology. 2009 Aug 20:1-20. [Epub ahead of print]
9. Cellular cardiac regenerative therapy in which patients?
Chachques JC.
Expert Rev Cardiovasc Ther. 2009 Aug;7(8):911-9.
10. Serological screening of Chagas disease in an immigrant population in Asturias,
Spain proceeding from Chagas-endemic areas.
Rodriguez-Guardado A, Rodriguez M, Alonso P, Seco C, Flores-Chavez M, Mejuto P,
Carton JA.
Scand J Infect Dis. 2009 Aug 14:1-3. [Epub ahead of print]
11. Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated
glycoprotein antigen as relevant candidate for vaccine development and drug target. A
review.
Duschak VG, Couto AS.
Curr Med Chem. 2009;16(24):3174-202.
12. Perforin and Interferon-{gamma} expression are required for CD4+ and CD8+ T celldependent protective immunity against a human parasite (Trypanosoma cruzi) elicited
by a heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.
de Alencar BC, Persechini PM, Haolla FA, de Oliveira G, Silverio JC, Lannes-Vieira J,
Machado AV, Gazzinelli RT, Bruna-Romero O, Rodrigues MM.
Infect Immun. 2009 Aug 3. [Epub ahead of print]
13. Plasma concentrations of tumour necrosis factor-alpha, tumour necrosis factorrelated apoptosis-inducing ligand, and FasLigand/CD95L in patients with Chagas
cardiomyopathy correlate with left ventricular dysfunction.
Lula JF, Rocha MO, Nunes Mdo C, Ribeiro AL, Teixeira MM, Bahia MT, Talvani A.
Eur J Heart Fail. 2009 Sep;11(9):825-31. Epub 2009 Aug 4.
Atenciosamente,
Andreia Dantas
Gestão PIDC
Tels.: 21-2562-1884/21-8811-1907
Homepages: www.fiocruz.br/pidc
www.fiocruz.br/chagas
www.fiocruz.br/chagas_esp
www.fiocruz.br/chagas_eng